Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.44 |
| ▸ | NNMT | P40261 | 4/20 | 0.41 |
| ▸ | HTRA2 | O43464 | 5/20 | 0.41 |
| ▸ | HTRA1 | Q92743 | 5/20 | 0.41 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RBBP5 | Q15291 | 2/20 | 0.41 |
| ▸ | DPY30 | Q9C005 | 2/20 | 0.41 |
| ▸ | ASH2L | Q9UBL3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31533321 | 0.94 | FOLH1 (0.42) | DOT1LNNMTWDR5KMT2ARBBP5 | |
| SCHEMBL30238998 | 0.89 | EPRS1 (0.44) | DOT1L | |
| SCHEMBL30239308 | 0.85 | HTRA2 (0.41) | DOT1LHTRA2HTRA1 | |
| SCHEMBL30238857 | 0.78 | DOT1L (0.55) | DOT1LNNMTWDR5KMT2ARBBP5 | |
| SCHEMBL31001633 | 0.76 | CA12 (0.48) | DOT1L | |
| SCHEMBL13977980 | 0.75 | NNMT (0.40) | DOT1LNNMT | |
| SCHEMBL17250042 | 0.75 | NNMT (0.41) | DOT1LNNMT | |
| SCHEMBL19434124 | 0.71 | DOT1L (0.46) | DOT1L | |
| SCHEMBL19429334 | 0.71 | DOT1L (0.46) | DOT1L | |
| SCHEMBL31001598 | 0.71 | CA12 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| EP-4374157-A2 | FRET-BASED ASSAYS | The General Hospital Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004438-A2 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | DOT1L 3975/4885NNMT 1586/4885HTRA2 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.